Matejka Rebolj1, Elsebeth Lynge2, Ditte Ejegod3, Sarah Preisler4, Carsten Rygaard3, Jesper Bonde4. 1. Department of Public Health, University of Copenhagen, Øster Farimagsgade 5, 1014 Copenhagen K, Denmark. Electronic address: matejka.rebolj@regionh.dk. 2. Department of Public Health, University of Copenhagen, Øster Farimagsgade 5, 1014 Copenhagen K, Denmark. 3. Department of Pathology, Copenhagen University Hospital Hvidovre, Kettegård Allé 30, 2650 Hvidovre, Denmark. 4. Department of Pathology, Copenhagen University Hospital Hvidovre, Kettegård Allé 30, 2650 Hvidovre, Denmark; Clinical Research Center, Copenhagen University Hospital Hvidovre, Kettegård Allé 30, 2650 Hvidovre, Denmark.
Abstract
OBJECTIVE: To compare the clinical characteristics of four human papillomavirus (HPV) assays: hybrid capture 2 (HC2), cobas, CLART, and APTIMA in Danish women with abnormal cytology. METHODS: SurePath samples from 367 consecutive women from Copenhagen, with atypical squamous cells of undetermined significance or worse, were tested with the four assays. These women were routinely recommended for repeated testing or were referred for colposcopy. Their worst histological diagnosis in 29 months from baseline was retrieved from the Danish National Pathology Data Bank. RESULTS: Of the 367 women, 16 (4%) had no follow-up, 232 (63%) had <CIN2, 35 (10%) had CIN2, 81 (22%) had CIN3, and 3 (1%) had cervical cancer. The sensitivity for ≥CIN3 was 95% (95% CI: 88-99) for HC2, 94% (95% CI: 87-98) for cobas, 93% (95% CI: 85-97) for CLART, and 87% (95% CI: 78-93) for APTIMA. In women of age above 30 years, the sensitivities were 98% (95% CI: 87-100), 93% (95% CI: 80-98), 90% (95% CI: 77-97), and 93% (95% CI: 80-98), respectively. One woman with cervical cancer tested negative on CLART and one on cobas; HC2 and APTIMA were positive in all three cancer cases. The specificity for <CIN3 was low for all assays and varied between 22% and 35%. Similar results were seen for ≥CIN2. CONCLUSIONS: Small differences in clinical characteristics were found for the four HPV assays in Danish women with abnormal cytology aged ≥30 years. At younger ages, APTIMA was somewhat less sensitive for high-grade CIN than the three HPV DNA assays.
OBJECTIVE: To compare the clinical characteristics of four human papillomavirus (HPV) assays: hybrid capture 2 (HC2), cobas, CLART, and APTIMA in Danish women with abnormal cytology. METHODS: SurePath samples from 367 consecutive women from Copenhagen, with atypical squamous cells of undetermined significance or worse, were tested with the four assays. These women were routinely recommended for repeated testing or were referred for colposcopy. Their worst histological diagnosis in 29 months from baseline was retrieved from the Danish National Pathology Data Bank. RESULTS: Of the 367 women, 16 (4%) had no follow-up, 232 (63%) had <CIN2, 35 (10%) had CIN2, 81 (22%) had CIN3, and 3 (1%) had cervical cancer. The sensitivity for ≥CIN3 was 95% (95% CI: 88-99) for HC2, 94% (95% CI: 87-98) for cobas, 93% (95% CI: 85-97) for CLART, and 87% (95% CI: 78-93) for APTIMA. In women of age above 30 years, the sensitivities were 98% (95% CI: 87-100), 93% (95% CI: 80-98), 90% (95% CI: 77-97), and 93% (95% CI: 80-98), respectively. One woman with cervical cancer tested negative on CLART and one on cobas; HC2 and APTIMA were positive in all three cancer cases. The specificity for <CIN3 was low for all assays and varied between 22% and 35%. Similar results were seen for ≥CIN2. CONCLUSIONS: Small differences in clinical characteristics were found for the four HPV assays in Danish women with abnormal cytology aged ≥30 years. At younger ages, APTIMA was somewhat less sensitive for high-grade CIN than the three HPV DNA assays.
Authors: Jack Cuzick; Amar S Ahmad; Janet Austin; Louise Cadman; Linda Ho; George Terry; Michelle Kleeman; Lesley Ashdown-Barr; Deirdre Lyons; Mark Stoler; Anne Szarewski Journal: J Clin Virol Date: 2016-07-27 Impact factor: 3.168
Authors: J U H Lam; K M Elfström; D M Ejegod; H Pedersen; C Rygaard; M Rebolj; E Lynge; K E Juul; S K Kjær; J Dillner; J Bonde Journal: Br J Cancer Date: 2017-11-14 Impact factor: 7.640
Authors: Ana Cristina L Macedo; João Carlos N Gonçalves; Daniela Vicente Bavaresco; Antonio José Grande; Napoleão Chiaramonte Silva; Maria Inês Rosa Journal: J Oncol Date: 2019-06-11 Impact factor: 4.375
Authors: Jesper Bonde; Fabio Bottari; Valentin Parvu; Helle Pedersen; Karen Yanson; Anna D Iacobone; Salma Kodsi; Fabio Landoni; Laurence Vaughan; Ditte M Ejegod; Maria T Sandri Journal: Int J Cancer Date: 2019-04-30 Impact factor: 7.396
Authors: J U H Lam; M Rebolj; D M Ejegod; H Pedersen; C Rygaard; E Lynge; E Harder; L T Thomsen; S K Kjaer; J Bonde Journal: J Clin Microbiol Date: 2017-07-19 Impact factor: 5.948